@article{04fe1a6e3dda4794ad239fd642348c1d,
title = "Reply to: Comments on “Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial”",
keywords = "Carcinoma, Ovarian Epithelial/drug therapy, Cytoreduction Surgical Procedures/methods, Female, Genomics, Humans, Hyperthermia, Induced/methods, Hyperthermic Intraperitoneal Chemotherapy, Ovarian Neoplasms/drug therapy",
author = "Koole, \{Simone N.\} and Schouten, \{Philip C.\} and \{van Driel\}, \{Willemien J.\} and Sonke, \{Gabe S.\} and Linn, \{Sabine C.\}",
note = "Funding Information: Philip C. Schouten is partner employed by AstraZeneca, with no direct connection to this work. Gabe S. Sonke reports consulting work for Biovica ans Seagen and research support paid to the institution from Agendia, AstraZeneca, Merck, Novartis, Roche and Seagen. Sabine C. Linn has been an advisory board member for AstraZeneca, Cergentis, IBM, Novartis, Pfizer, Roche and Sanofi, and has received unrestricted institutional research support of unrestricted educational funding from Agendia, Amgen, AstraZeneca, Bayer, Daiichi Sankyo, Eurocept Pharmaceuticals, Genentech, Immunomedics, Merck, Roche, Sanofi and TESARO. Sabine C. Linn has a patent application pending on a BRCA‐like ovarian cancer classifier. All other authors declare no conflicts of interest.",
year = "2022",
month = dec,
day = "1",
doi = "10.1002/ijc.34219",
language = "English",
volume = "151",
pages = "2057--2058",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "John Wiley \& Sons Inc.",
number = "11",
}